Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD), Part II

NCT05202327 is registered in ClinicalTrials.gov with BioLite, Inc. as lead sponsor.

NCT NCT05202327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05202327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD), Part II
Lead sponsor
BioLite, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 7, 2022
Completion date
April 8, 2024
Enrollment
99 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

attention-deficit hyperactivity disorder (adhd)